Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

A temporal and spatial map of axons in developing mouse prostate.

Turco AE, Cadena MT, Zhang HL, Sandhu JK, Oakes SR, Chathurvedula T, Peterson RE, Keast JR, Vezina CM.

Histochem Cell Biol. 2019 Jul;152(1):35-45. doi: 10.1007/s00418-019-01784-6. Epub 2019 Apr 11.

PMID:
30976911
2.

The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.

Alexandrou S, George SM, Ormandy CJ, Lim E, Oakes SR, Caldon CE.

Int J Mol Sci. 2019 Feb 4;20(3). pii: E667. doi: 10.3390/ijms20030667. Review.

3.

Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology.

Valdes-Mora F, Handler K, Law AMK, Salomon R, Oakes SR, Ormandy CJ, Gallego-Ortega D.

Front Immunol. 2018 Nov 12;9:2582. doi: 10.3389/fimmu.2018.02582. eCollection 2018. Review.

4.

Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy.

Marini KD, Croucher DR, McCloy RA, Vaghjiani V, Gonzalez-Rajal A, Hastings JF, Chin V, Szczepny A, Kostyrko K, Marquez C, Jayasekara WSN, Alamgeer M, Boolell V, Han JZR, Waugh T, Lee HC, Oakes SR, Kumar B, Harrison CA, Hedger MP, Lorensuhewa N, Kita B, Barrow R, Robinson BW, de Kretser DM, Wu J, Ganju V, Sweet-Cordero EA, Burgess A, Martelotto LG, Rossello FJ, Cain JE, Watkins DN.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaat3504. doi: 10.1126/scitranslmed.aat3504.

PMID:
30045976
5.

Void spot assay procedural optimization and software for rapid and objective quantification of rodent voiding function, including overlapping urine spots.

Wegner KA, Abler LL, Oakes SR, Mehta GS, Ritter KE, Hill WG, Zwaans BM, Lamb LE, Wang Z, Bjorling DE, Ricke WA, Macoska J, Marker PC, Southard-Smith EM, Eliceiri KW, Vezina CM.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1067-F1080. doi: 10.1152/ajprenal.00245.2018. Epub 2018 Jul 4.

PMID:
29972322
6.

Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion.

Young AI, Timpson P, Gallego-Ortega D, Ormandy CJ, Oakes SR.

Cell Adh Migr. 2018;12(6):513-523. doi: 10.1080/19336918.2017.1393591. Epub 2017 Dec 21.

7.

Andy's Algorithms: new automated digital image analysis pipelines for FIJI.

Law AMK, Yin JXM, Castillo L, Young AIJ, Piggin C, Rogers S, Caldon CE, Burgess A, Millar EKA, O'Toole SA, Gallego-Ortega D, Ormandy CJ, Oakes SR.

Sci Rep. 2017 Nov 16;7(1):15717. doi: 10.1038/s41598-017-15885-6.

8.

A mutation in the viral sensor 2'-5'-oligoadenylate synthetase 2 causes failure of lactation.

Oakes SR, Gallego-Ortega D, Stanford PM, Junankar S, Au WWY, Kikhtyak Z, von Korff A, Sergio CM, Law AMK, Castillo LE, Allerdice SL, Young AIJ, Piggin C, Whittle B, Bertram E, Naylor MJ, Roden DL, Donovan J, Korennykh A, Goodnow CC, O'Bryan MK, Ormandy CJ.

PLoS Genet. 2017 Nov 8;13(11):e1007072. doi: 10.1371/journal.pgen.1007072. eCollection 2017 Nov.

9.

MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.

Young AI, Law AM, Castillo L, Chong S, Cullen HD, Koehler M, Herzog S, Brummer T, Lee EF, Fairlie WD, Lucas MC, Herrmann D, Allam A, Timpson P, Watkins DN, Millar EK, O'Toole SA, Gallego-Ortega D, Ormandy CJ, Oakes SR.

Breast Cancer Res. 2016 Dec 8;18(1):125.

10.

ELF5 isoform expression is tissue-specific and significantly altered in cancer.

Piggin CL, Roden DL, Gallego-Ortega D, Lee HJ, Oakes SR, Ormandy CJ.

Breast Cancer Res. 2016 Jan 7;18(1):4. doi: 10.1186/s13058-015-0666-0.

11.

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.

Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A, Kikhtyak Z, Cho C, Allerdice SL, Lee HJ, Valdes-Mora F, Herrmann D, Salomon R, Young AI, Lee BY, Sergio CM, Kaplan W, Piggin C, Conway JR, Rabinovich B, Millar EK, Oakes SR, Chtanova T, Swarbrick A, Naylor MJ, O'Toole S, Green AR, Timpson P, Gee JM, Ellis IO, Clark SJ, Ormandy CJ.

PLoS Biol. 2015 Dec 30;13(12):e1002330. doi: 10.1371/journal.pbio.1002330. eCollection 2015 Dec.

12.

Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease.

Hilton HN, Doan TB, Graham JD, Oakes SR, Silvestri A, Santucci N, Kantimm S, Huschtscha LI, Ormandy CJ, Funder JW, Simpson ER, Kuczek ES, Leedman PJ, Tilley WD, Fuller PJ, Muscat GE, Clarke CL.

Oncotarget. 2014 Sep 30;5(18):8651-64.

13.

The mammary cellular hierarchy and breast cancer.

Oakes SR, Gallego-Ortega D, Ormandy CJ.

Cell Mol Life Sci. 2014 Nov;71(22):4301-24. doi: 10.1007/s00018-014-1674-4. Epub 2014 Jul 31. Review.

14.

Therapeutic targets in triple negative breast cancer.

O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A, Oakes SR.

J Clin Pathol. 2013 Jun;66(6):530-42. doi: 10.1136/jclinpath-2012-201361. Epub 2013 Feb 22. Review.

PMID:
23436929
15.

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ.

PLoS Biol. 2012;10(12):e1001461. doi: 10.1371/journal.pbio.1001461. Epub 2012 Dec 27.

16.

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.

Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, Lindeman GJ.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2766-71. doi: 10.1073/pnas.1104778108. Epub 2011 Jul 18.

17.

High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype.

Zardawi SJ, Zardawi I, McNeil CM, Millar EK, McLeod D, Morey AL, Crea P, Murphy NC, Pinese M, Lopez-Knowles E, Oakes SR, Ormandy CJ, Qiu MR, Hamilton A, Spillane A, Soon Lee C, Sutherland RL, Musgrove EA, O'Toole SA.

Histopathology. 2010 Feb;56(3):286-96. doi: 10.1111/j.1365-2559.2009.03475.x.

PMID:
20459529
18.

Notch signaling regulates mammary stem cell function and luminal cell-fate commitment.

Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, Lindeman GJ, Visvader JE.

Cell Stem Cell. 2008 Oct 9;3(4):429-41. doi: 10.1016/j.stem.2008.08.001.

19.

The Ets transcription factor Elf5 specifies mammary alveolar cell fate.

Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ.

Genes Dev. 2008 Mar 1;22(5):581-6. doi: 10.1101/gad.1614608.

20.

Prolactin regulation of mammary gland development.

Oakes SR, Rogers RL, Naylor MJ, Ormandy CJ.

J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):13-28. doi: 10.1007/s10911-008-9069-5. Epub 2008 Jan 25. Review.

PMID:
18219564
21.

KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling.

Hilton HN, Stanford PM, Harris J, Oakes SR, Kaplan W, Daly RJ, Ormandy CJ.

Biochim Biophys Acta. 2008 Mar;1783(3):383-93. doi: 10.1016/j.bbamcr.2007.12.007. Epub 2008 Jan 9.

22.
23.

Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions.

Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE, Ormandy CJ.

Oncogene. 2007 Jan 25;26(4):543-53. Epub 2006 Jul 24.

PMID:
16862169
24.

Organic chemicals in sewage sludges.

Harrison EZ, Oakes SR, Hysell M, Hay A.

Sci Total Environ. 2006 Aug 31;367(2-3):481-97. Epub 2006 Jun 5. Review.

PMID:
16750559
25.
26.

Socs2 and elf5 mediate prolactin-induced mammary gland development.

Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG, Blazek KD, Kazlauskas M, Hilton HN, Wittlin S, Alexander WS, Lindeman GJ, Visvader JE, Ormandy CJ.

Mol Endocrinol. 2006 May;20(5):1177-87. Epub 2006 Feb 9.

PMID:
16469767
27.

Transcriptional changes underlying the secretory activation phase of mammary gland development.

Naylor MJ, Oakes SR, Gardiner-Garden M, Harris J, Blazek K, Ho TW, Li FC, Wynick D, Walker AM, Ormandy CJ.

Mol Endocrinol. 2005 Jul;19(7):1868-83. Epub 2005 Feb 10.

PMID:
15705664
28.

Prolactin and the prolactin receptor: new targets of an old hormone.

Harris J, Stanford PM, Oakes SR, Ormandy CJ.

Ann Med. 2004;36(6):414-25. Review.

PMID:
15513293
29.

The cyclin-dependent kinase inhibitor p27 (Kip1) regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy.

Davison EA, Lee CS, Naylor MJ, Oakes SR, Sutherland RL, Hennighausen L, Ormandy CJ, Musgrove EA.

Mol Endocrinol. 2003 Dec;17(12):2436-47. Epub 2003 Aug 21.

PMID:
12933906
30.

Prostate development and carcinogenesis in prolactin receptor knockout mice.

Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, Wennbo H, Törnell J, Kelly PA, Green J, Ormandy CJ.

Endocrinology. 2003 Jul;144(7):3196-205.

PMID:
12810576
31.

Y4 receptor knockout rescues fertility in ob/ob mice.

Sainsbury A, Schwarzer C, Couzens M, Jenkins A, Oakes SR, Ormandy CJ, Herzog H.

Genes Dev. 2002 May 1;16(9):1077-88.

32.

Immunoreactive growth hormone receptor/binding protein is present on fibroblasts and in serum of Laron-type dwarfs.

Oakes SR, Haynes KM, Batch J, Ennis G, Waters MJ, Daughaday W, Herington AC, Werther GA.

Mol Cell Endocrinol. 1994 Feb;99(1):125-32.

PMID:
8187955
33.

Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts.

Oakes SR, Haynes KM, Waters MJ, Herington AC, Werther GA.

J Clin Endocrinol Metab. 1992 Nov;75(5):1368-73.

PMID:
1430099

Supplemental Content

Loading ...
Support Center